Subjects aged 20 years or older who applied the combination of SGLT2i and GLP-1RA from January 2016 to September 2020 (*n*=213)



Supplementary Fig. 1. Flow diagram showing the selection of the study population. SGLT2i, sodium-glucose cotransporter 2 inhibitor; GLP-1RA, glucagon-like peptide-1 receptor agonist; eGFR, estimated glomerular filtration rate.